Global Drug Delivery Systems (DDS) Markets 2021-2027 - Increasing R&D Expenditures of Innovator Companies and the Trend of Patent Portfolio Expansion prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Oral Biologics Market to Surpass US$ 11,907.2 Million by 2028, Says Coherent Market Insights (CMI)
May 7, 2021 GMT
SEATTLE (BUSINESS WIRE) May 7, 2021
According to Coherent Market Insights, the global oral biologics market is estimated to be valued at
US$ 1,437.4 million in
2021 and is expected to exhibit a
CAGR of
(2021-2028).
Key Trends and Analysis of the Global Oral Biologics Market:
Key players are focused on strategies such as fund raising to boost their research and development of oral biologics for treatment of various chronic diseases such as diabetes, inflammatory bowel diseases, and others, which is expected to drive the market growth.
How Rani Therapeutics’ robotic pill could change subcutaneous injection treatment
A new auto-injecting pill might soon become a replacement for subcutaneous injection treatments.
The idea for this so-called robotic pill came out of a research project around eight years ago from InCube Labs a life sciences lab operated by Rani Therapeutics Chairman and CEO Mir Imran, who has degrees in electrical and biomedical engineering from Rutgers University. A prominent figure in life sciences innovation, Imran has founded more than 20 medical device companies and helped develop the world’s first implantable cardiac defibrillator.
In working on the technology behind San Jose-based Rani Therapeutics, Imran and his team wanted to find a way to relieve some of the painful side effects of subcutaneous (or under-the-skin) injections, while also improving the treatment’s efficacy. “The technology itself started with a very simple thesis,” said Imran in an interview. “We thought, why c
Rani Therapeutics, a clinical-stage biopharma company and developer of the RaniPill robotic pill, today announced that it has raised US$69m in a Series E financing round, bringing total funding to date to US$211.
Rani Therapeutics Raises $69 Million Series E To Advance Clinical Trials And Manufacturing Of Robotic Pill
News provided by
Share this article
Share this article
SAN JOSE, Calif., Dec. 10, 2020 /PRNewswire/ Rani Therapeutics, a clinical-stage biopharmaceutical company and developer of the RaniPill™ robotic pill, today announced that it has raised $69 million in a Series E financing, bringing the total funding to $211 million. BofA Securities acted as financial advisor to the company.
The company s platform technology converts injectable drugs like PTH and adalimumab into pills. The market potential of the RaniPill™ to replace injectable biologics with oral versions, represents multiple billion-dollar opportunities for diabetes, arthritis, psoriasis, hemophilia and other diseases.